Report details possible conflict of interest issues for FDA advisors

July 6, 2018 by Bob Yirka, Medical Xpress report
Credit: CC0 Public Domain

Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the FDA. In his report, he offers examples of what he describes as possible conflicts of interest. He also suggests the FDA might want to review its rules regarding what advisors can and cannot do after they have served in an advisory role for the agency.

The Food and Drug Agency is tasked with providing a safeguard for the public. Food and drugs proposed by business entities are reviewed by teams at the agency and must win a seal of approval before they are allowed to sell a product to the public. As part of this process, the FDA calls in expert advisors to offer testimony or advice on given products, such as . In his report, Piller focuses on people who worked as advisors for the FDA who later received what could be perceived as compensation from those they have reviewed, for their efforts. He and associate Jia You looked at publicly available data concerning 107 doctor advisors and found that 40 of them received benefits such as payment for hotels or research grants. More than half of them, he notes, received over $100,000 in such "gifts," and seven of them got more than $1 million worth. And none of the payments were reported by the FDA. One doctor in particular, he notes, received $1.9 million from a pharmaceutical company after one of its drugs was approved by a panel on which that doctor had been an advisor.

In a related segment, Piller notes that it is not just advisors who might be engaging in questionable activities. He notes that one former director for the agency who was once involved in reviewing drugs now operates a consulting business that offers advice to pharmaceutical companies on how to get their drugs approved.

Piller sums up his paper by suggesting that it might be time for the FDA to shore up its non-compete contracts for both advisors and employees—doing so, he notes would eliminate the possibility of such people making decisions that are in their own best interests rather than those of the public.

Explore further: Patient, family advisors can play key role in practices

More information: Charles Piller. Hidden conflicts?, Science (2018). DOI: 10.1126/science.361.6397.16

An investigative report uncovers little recognized and unpoliced potential conflicts of interest among those who serve on FDA advisory panels that review drugs. Some members of such panels are later receiving significant payments from either the makers of drugs they previously reviewed, or from competitors. This is happening despite the FDA's established system to identify possible financial conflicts of interest among those recruited for the drug advisory panels. The investigation analyzed records on the federal Open Payments website between 2013 and 2016. Of 107 physician advisors who voted on FDA advisory committees during this time, 26 later took more than $100,000 from the makers of drugs, or from competing firms. in post-hoc earnings or research support. Even though these payments might not be truly "quid-pro-quo," according to Vinay Prasad, an oncologist who also studies financial conflicts that exist in drug approvals, those asked to weigh in stand to gain tremendously in their further professional careers. "It's in their best interest to play nice with the companies." FDA may also have missed or judged insignificant financial ties physicians had before their service on the drug approval advisory panels.

Related Stories

Patient, family advisors can play key role in practices

August 23, 2015
(HealthDay)—Practices can employ patient and family advisors in order to help them focus on patient-centered care needs, according to a report published by the American Medical Association (AMA).

How can lay health advisor programs be designed for maximum impact?

April 14, 2016
Lay health advisors who share similar social, economic, cultural and linguistic backgrounds and values with the medically underserved groups they interact with have been shown to reduce health disparities. Looking to identify ...

FDA approves drugs more quickly than peer agency in Europe: study

April 5, 2017
The U.S. Food and Drug Administration (FDA) reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency (EMA), says a Yale researcher. This finding, which comes ...

Pharmaceutical companies: An $84 million marketing effort in the District of Columbia

March 1, 2013
Drug companies spent nearly $84 million marketing pharmaceuticals in the District of Columbia in 2011, including an outlay of nearly $19 million for gifts given to physicians, hospitals and other health care providers, according ...

Recommended for you

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

One in four older adults prescribed a benzodiazepine goes on to risky long-term use

September 10, 2018
They may start as well-intentioned efforts to calm anxiety, improve sleep or ease depression. But prescriptions for sedatives known as benzodiazepines may lead to long-term use among one in four older adults who receive them, ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jul 06, 2018
oh gee there's a big surprise. Well known fact. We value money above people. Patent driven model is itself one big conflict of interest.
3 / 5 (2) Jul 07, 2018
For anyone who would defend this business model. Can you name even one instance, where corporate interests ever prevented defective products from being sold to the public?
not rated yet Jul 07, 2018
One thing China does right is a death penalty for corruption.
not rated yet Jul 08, 2018
For anyone who would defend this business model. Can you name even one instance, where corporate interests ever prevented defective products from being sold to the public?
"Validation is the process of establishing documentary evidence demonstrating that a procedure, process, or activity carried out in testing and then production maintains the desired level of compliance at all stages."

-If a manufacturing process cant be validated then it doesnt get made. 1000s of examples. In fact you MORON this industry is one of the most highly self-regulated of any of them.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.